ATE368054T1 - Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität - Google Patents

Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität

Info

Publication number
ATE368054T1
ATE368054T1 AT98963311T AT98963311T ATE368054T1 AT E368054 T1 ATE368054 T1 AT E368054T1 AT 98963311 T AT98963311 T AT 98963311T AT 98963311 T AT98963311 T AT 98963311T AT E368054 T1 ATE368054 T1 AT E368054T1
Authority
AT
Austria
Prior art keywords
modulating agents
occludin
cell adhesion
methods
compounds
Prior art date
Application number
AT98963311T
Other languages
English (en)
Inventor
Orest W Blaschuk
Barbara Gour
James Matthew Symonds
Original Assignee
Adherex Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adherex Technologies Inc filed Critical Adherex Technologies Inc
Application granted granted Critical
Publication of ATE368054T1 publication Critical patent/ATE368054T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT98963311T 1997-12-31 1998-12-30 Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität ATE368054T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/001,511 US6248864B1 (en) 1997-12-31 1997-12-31 Compounds and methods and modulating tissue permeability

Publications (1)

Publication Number Publication Date
ATE368054T1 true ATE368054T1 (de) 2007-08-15

Family

ID=21696412

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98963311T ATE368054T1 (de) 1997-12-31 1998-12-30 Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität

Country Status (9)

Country Link
US (3) US6248864B1 (de)
EP (1) EP1042365B1 (de)
JP (1) JP2002509073A (de)
AT (1) ATE368054T1 (de)
AU (1) AU764790B2 (de)
CA (1) CA2351624A1 (de)
DE (1) DE69838147T2 (de)
ES (1) ES2292211T3 (de)
WO (1) WO1999035166A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6797807B1 (en) * 1997-12-31 2004-09-28 Adherex Technologies, Inc. Compounds and methods for cancer therapy
ES2341926T3 (es) * 1998-03-02 2010-06-29 Massachusetts Institute Of Technology Poliproteinas con dedos de cinc que tienen enlazadores mejorados.
US6391855B1 (en) * 1999-06-02 2002-05-21 Adherex Technologies, Inc. Compounds and methods for modulating junctional adhesion molecule-mediated functions
DE60044904D1 (de) * 1999-09-03 2010-10-14 Brigham & Womens Hospital Verfahren und zusammensetzungen zur behandlung von entzündungskrankheiten unter verwendung von cadherin-11-modulierenden agenzien
US6787136B1 (en) 1999-09-03 2004-09-07 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
US20030153015A1 (en) * 2000-01-20 2003-08-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA2398155C (en) * 2000-01-24 2011-07-19 Sangamo Biosciences, Inc. Methods and compositions for linking binding domains in nucleic acid binding proteins
US20020077775A1 (en) * 2000-05-25 2002-06-20 Schork Nicholas J. Methods of DNA marker-based genetic analysis using estimated haplotype frequencies and uses thereof
US20030195707A1 (en) * 2000-05-25 2003-10-16 Schork Nicholas J Methods of dna marker-based genetic analysis using estimated haplotype frequencies and uses thereof
EP1309682A2 (de) * 2000-07-14 2003-05-14 Chiron Corporation Tetraspan protein und dessen verwendung
WO2002034880A2 (en) * 2000-10-23 2002-05-02 University Of Kansas Cadherin peptides for drug delivery and inhibition of tumor metastasis/invasion
US20020192206A1 (en) * 2001-05-05 2002-12-19 Kozarov Emil V. Methods and compositions for angioproliferative disorder treatment
WO2003014151A2 (en) * 2001-08-10 2003-02-20 Genset S.A. Human secreted proteins, their encoding polynucleotides, and uses thereof
US20050123925A1 (en) * 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2003102538A2 (en) * 2002-05-30 2003-12-11 European Molecular Biology Laboratory Combinatorial chemical library ii
WO2004003145A2 (en) * 2002-06-28 2004-01-08 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
EP1384468A1 (de) * 2002-07-25 2004-01-28 Cognis France S.A. Verfahren zum Schutz und zur Modulation von Tight Junctions
EP1384469A1 (de) * 2002-07-25 2004-01-28 Cognis France S.A. Verfahren zum Schutz und zur Modulation von Tight Junctions
CA2504768A1 (en) * 2002-11-14 2004-05-27 Adherex Technologies, Inc. Compounds and methods for modulating functions of classical cadherins
CA2506037A1 (en) * 2002-11-14 2004-06-10 Adherex Technologies, Inc. Compounds and methods for modulating desmosomal and atypical cadherin-mediated cell adhesion
CA2523870A1 (en) * 2003-04-30 2004-11-18 Nastech Pharmaceutical Company Inc. Claudins' underexpression as markers of tumor metastasis
US20050129679A1 (en) * 2003-12-15 2005-06-16 Nastech Pharmaceutical Company Inc. Method for opening tight junctions
US20080125364A1 (en) * 2004-12-28 2008-05-29 Asma Nusrat Methods and Compositions for Treating Epithelial Cancers
KR101203328B1 (ko) * 2005-04-26 2012-11-20 화이자 인코포레이티드 Ｐ-카드헤린 항체
US7803778B2 (en) 2006-05-23 2010-09-28 Theracos, Inc. Glucose transport inhibitors and methods of use
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
CN101652377A (zh) 2007-04-02 2010-02-17 泰拉科斯有限公司 苄基化糖苷衍生物及其用法
US7838499B2 (en) 2007-08-23 2010-11-23 Theracos, Inc. Benzylbenzene derivatives and methods of use
US8563515B2 (en) * 2007-11-19 2013-10-22 The Regents Of The University Of Colorado, A Body Corporate Tight junction protein modulators and uses thereof
CN102149280B (zh) 2008-07-15 2017-05-24 泰拉科斯有限公司 氘化苄基苯衍生物及其使用方法
ME02702B (de) 2008-08-22 2017-10-20 Theracos Sub Llc Verfahren zur herstellung von sglt2-hemmern
US8940960B2 (en) 2008-10-03 2015-01-27 The Rockefeller University HCV entry factor, Occludin
CN102264743B (zh) 2008-11-25 2015-02-11 罗彻斯特大学 Mlk抑制剂及其使用方法
CA2764526A1 (en) 2009-06-24 2010-12-29 Christine Kritikou The use of spinosyns and spinosyn compositions against diseases caused by protozoans, viral infections and cancer
US8877188B2 (en) 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis
NZ603644A (en) 2010-05-24 2014-10-31 Univ Rochester Bicyclic heteroaryl kinase inhibitors and methods of use
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
EP2654757A1 (de) 2010-12-22 2013-10-30 Entarco SA Verwendung von spinosynen und spinosynzusammensetzungen als lokalanästhetika und antiarrhythmika
WO2012112933A1 (en) 2011-02-18 2012-08-23 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
EP2925319B1 (de) 2012-11-30 2019-01-09 University Of Rochester Mixed-lineage-kinaseinhibitoren für hiv/aids-therapien
JP6076509B2 (ja) * 2014-02-07 2017-02-08 ミヤリサン製薬株式会社 クロストリジウム属の菌の毒素産生抑制活性を有するペプチド
EP3119394B1 (de) 2014-03-19 2021-05-12 Curza Global LLC Zusammensetzungen und verfahren mit 2-(acylamino)imidazolen
US11097005B2 (en) 2014-12-15 2021-08-24 The Brigham And Women's Hospital, Inc. Use of cadherin-11 antagonists to treat metabolic disorders and/or increase insulin sensitivity
CN108084257B (zh) * 2016-11-23 2020-06-12 深圳市安群生物工程有限公司 人闭锁蛋白抗原表位肽、抗原、抗体、试剂盒及应用
WO2018184019A1 (en) 2017-03-31 2018-10-04 Curza Global, Llc Compositions and methods comprising substituted 2-aminoimidazoles
TW202023625A (zh) 2018-08-23 2020-07-01 美商西雅圖遺傳學公司 抗tigit抗體
EP4240415A1 (de) 2020-11-08 2023-09-13 Seagen Inc. Kombinationstherapie-antikörper-wirkstoff-konjugat mit immunzellenhemmer
IL307556A (en) 2021-04-09 2023-12-01 Seagen Inc Cancer treatment methods using antibodies against TIGIT
WO2024191807A1 (en) 2023-03-10 2024-09-19 Seagen Inc. Methods of treating cancer with anti-tigit antibodies
KR20240158158A (ko) * 2023-04-26 2024-11-04 서울대학교산학협력단 C-n 결합으로 환형화된 새로운 환형 펩타이드계열 화합물, 이의 생산 방법 및 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69735872T2 (de) 1996-03-07 2006-12-28 Eisai Co., Ltd. Menschliches adhäsionsmolekül occludin
US6252045B1 (en) 1996-03-15 2001-06-26 Yale University Human occludin, its uses and enhancement of drug absorption using occludin inhibitors
US6214795B1 (en) * 1996-11-12 2001-04-10 Praecis Pharmaceuticals, Inc. Peptide compounds useful for modulating FGF receptor activity

Also Published As

Publication number Publication date
DE69838147D1 (de) 2007-09-06
DE69838147T2 (de) 2008-05-29
WO1999035166A1 (en) 1999-07-15
US6310177B1 (en) 2001-10-30
EP1042365A1 (de) 2000-10-11
AU1866599A (en) 1999-07-26
JP2002509073A (ja) 2002-03-26
US6110747A (en) 2000-08-29
ES2292211T3 (es) 2008-03-01
AU764790B2 (en) 2003-08-28
EP1042365B1 (de) 2007-07-25
CA2351624A1 (en) 1999-07-15
US6248864B1 (en) 2001-06-19

Similar Documents

Publication Publication Date Title
ATE368054T1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
DE69832293D1 (de) Zubereitungen zur abgabe von negativ geladenen molekülen
DK0922102T3 (da) Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
TR200301846T2 (tr) Cripto bloke edici Antikorlar ve bu antikorların kullanımları.
DE60332277D1 (de) Verabreichung von sirnas
BR0207775A (pt) Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
ATE410441T1 (de) Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidinanalogen
DK1053256T3 (da) Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf
ATE345682T1 (de) In vitro verfahren zum einbringen von nukleinsäuren in eine zelle
DK1093383T3 (da) Lægemiddelafgivelsessystem omfattende et homeobox-peptid og et cytotoksisk eller antineoplastisk lægemiddel
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
DE60006100D1 (de) Lang wirkende insulinotrope peptide
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
DE60032486D1 (de) Prion protein peptide und deren verwendung
WO1999016791A3 (en) Compounds and methods for regulating cell adhesion
DK1123414T3 (da) Antisense-modulering af integrin alpha 4.ekspression
NO971341D0 (no) Promoter for reseptor tyrosinkinase TIE
DE60113445D1 (de) Substanzen mit verzweigten linkermolekülen
EP1401467A4 (de) Alpha-fetoprotein-peptide und ihre verwendung
ATE414100T1 (de) Zielgerichtete ligande gegen peyer's flecke- und/oder m-zellen
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
DK0952982T3 (da) Hidtil ukendte hepatitis B inhibitorer
DE69733948D1 (de) In vivo herstellung von replicativen molekülen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties